PROBLEM

Lacking data and targets?

The industry’s biggest challenge is that it is difficult to obtain enough usable and actionable data that results in novel drug targets. This makes even the best organisations fall behind the competition.

10+ Years

Drug discovery is a long process, often taking over 10 years to find the right targets

Unusable Data

Data is not standardized and is difficult to access

Limited Insights

Analysis is often limited to pre-configured tools

Unverifiable Insights

Difficult to verify targets without clinical records

Only with the right data, you avoid going from

from_to_graphic

 

SOLUTION

Connect to the world’s unused data to obtain novel therapeutic insights
We believe that all data that can be used to cure diseases, should be used.
150+​

Biobanks and Population Genomics initiatives making their biomedical data available

10M+​

Datasets within our network,
ranging from cancer to rare diseases

100M+

Real World Evidence data points
in our real time learning knowledge graph

The Lifebit Experience

Using Lifebit's pioneering
federated data catalogue
to access data virtually


1. Secure access
to internal data

Manage your data via our ISO 27001 certified, security by design platform.
2. Collaborate across distributed data

Identify diverse cohorts to support and advance key therapeutic areas.
3. Innovate with your data and analysis technology 

Fast track research with large-scale cohorts & advanced analytics to improve patient outcomes.


Talk to an expert
quote

This platform will play an important part of Boehringer Ingelheim’s broader strategy to capture translational disease insights from large external healthcare biobanks and ultimately to accelerate the development of innovative medicines.

Anne-Deslattes-Mays-low-v02 1 (1)
trusted-research-environment-boehringer-ingelheim-mobile-280x86px-2
Dr. Jan Nygaard Jensen

SVP & Global Head of Computational Biology & Digital Sciences

quote

''Omica.bio and Lifebit share a common commitment to never let the lack of data stand in the way of scientific progress. This partnership presents an exciting opportunity to bring the genetic diversity of Latin American populations to the global research agenda. This has the potential to transform global research endeavours whilst also directly benefiting people in Latin America.”

Victor Angel-Mosti
Omica_Bio_Logo
Victor Angel-Mosti

CEO and Founder of Omica.bio

Get started

1

Book a consultation
with our data experts

2

Choose disease
& use case

3

Get the right data
& drug discovery
results in <3 clicks

Book a demo

 

 

 

Here to help_Thorben

 

Discover how Lifebit Connect facilitates secure access to disparate, diverse data globally to power your drug discovery


Our experts are ready to help

Resourses

gent_omica_announcement_BLOG_Featured (1)


Lifebit partners with Latin American innovators to help solve global health challenges through genomics research




Read more
Blog_Fed_Data_Analysis_Featured (2)


What is federated data analysis?






 

 

Read more
Blog_Complete Guide to Fed - featured img (1) (1)


The complete guide to federated data analysis



 

 

Read more